The new cystic fibrosis drug Kalydeco illustrates both the promise and peril of personalized medicine: It is extremely expensive and helps only 4% of people with the disease, or 1200 patients.
No takes yet. Share an insight, caveat, or question.
Jocelyn Kaiser (2012) studied this question.